Literature DB >> 2463995

Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections.

D Cohen1, C Block, M S Green, G Lowell, I Ofek.   

Abstract

The antilipopolysaccharide antibody response in sera obtained from subjects involved in 10 outbreaks of shigellosis occurring in Israeli military field units was determined by an enzyme-linked immunosorbent assay and a passive hemagglutination test. Both tests were found to be sensitive and specific for the diagnosis of shigellosis. A significant antibody response was detected in 73 to 82% of the symptomatic and 48 to 60% of the asymptomatic subjects during the Shigella sonnei and Shigella flexneri outbreaks. Fifty percent of the symptomatic and none of the asymptomatic subjects showed a significant antibody response in the Shigella boydii outbreaks. An examination of the kinetics of the antibody levels over a 10-week period after the onset of disease revealed that immunoglobulin A (IgA) levels were highest 2 weeks after infection and had declined to initial levels within 2.5 months. In contrast, IgG levels at the late convalescent stage were half those measured at early convalescence, still being about twice as high as the initial titers. Although the IgM levels showed a pattern similar to that of IgA, their elevation at the early convalescent stage was less pronounced. We conclude that the detection of an increase in the level of the IgA fraction appeared to be the best indicator for recent symptomatic, as well as symptomatic, infections due to Shigella organisms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2463995      PMCID: PMC267253          DOI: 10.1128/jcm.27.1.162-167.1989

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Epidemiologic and immunologic studies of Shigella sonnei dysentery.

Authors:  E NETER
Journal:  Am J Public Health Nations Health       Date:  1962-01

2.  Enzyme-linked immunosorbent assay for immunoglobulin G and immunoglobulin A antibodies to Shigella flexneri antigens.

Authors:  D F Keren
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

3.  Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines.

Authors:  M M Levine; H L Dupont; E J Gangarosa; R B Hornick; M J Snyder; J P Libonati; K Glaser; S B Formal
Journal:  Am J Epidemiol       Date:  1972-07       Impact factor: 4.897

4.  Epidemic Shiga bacillus dysentery in Central America. I. Etiologic investigations in Guatemala, 1969.

Authors:  L J Mata; E J Gangarosa; A Cáceres; D R Perera; M L Mejicanos
Journal:  J Infect Dis       Date:  1970-09       Impact factor: 5.226

5.  Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.

Authors:  E Engvall; P Perlmann
Journal:  Immunochemistry       Date:  1971-09

6.  Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.

Authors:  D Cohen; M S Green; C Block; T Rouach; I Ofek
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

7.  Antibody response to Shigella sonnei infection determined by an enzyme-linked immunosorbent assay.

Authors:  E Ekwall; S Haeggmann; M Kalin; B Svenungsson; A A Lindberg
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

8.  Microtiter bacterial hemagglutination technique for detection of Shigella antibodies.

Authors:  M R Lee; N S Ikari; W C Branche; V M Young
Journal:  J Bacteriol       Date:  1966-01       Impact factor: 3.490

9.  The humoral antibody response to Shigella dysenteriae type 1 infection, as determined by ELISA.

Authors:  A A Lindberg; S Haeggman; K Karlsson; D C Phung; D T Dang
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

10.  Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans.

Authors:  M M Levine; D Herrington; J R Murphy; J G Morris; G Losonsky; B Tall; A A Lindberg; S Svenson; S Baqar; M F Edwards
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

  10 in total
  42 in total

1.  Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.

Authors:  Nadav Orr; David E Katz; Jacob Atsmon; Paull Radu; Miri Yavzori; Tamar Halperin; Tamar Sela; Raid Kayouf; Zivit Klein; Ruhama Ambar; Dani Cohen; Marcia K Wolf; Malabi M Venkatesan; Thomas L Hale
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.

Authors:  D Cohen; S Ashkenazi; M Green; Y Lerman; R Slepon; G Robin; N Orr; D N Taylor; J C Sadoff; C Chu; J Shiloach; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

3.  Immune response against lipopolysaccharide and invasion plasmid-coded antigens of shigellae in Vietnamese and Swedish dysenteric patients.

Authors:  P D Cam; T Pál; A A Lindberg
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

Review 4.  Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis.

Authors:  Dani Cohen; Shiri Meron-Sudai; Anya Bialik; Valeria Asato; Sophy Goren; Ortal Ariel-Cohen; Arava Reizis; Amit Hochberg; Shai Ashkenazi
Journal:  Hum Vaccin Immunother       Date:  2019-05-09       Impact factor: 3.452

5.  Establishment of a Shigella sonnei human challenge model in Thailand.

Authors:  Ladaporn Bodhidatta; Punnee Pitisuttithum; Supat Chamnanchanant; Karen T Chang; Dilara Islam; Valai Bussaratid; Malabi M Venkatesan; Thomas L Hale; Carl J Mason
Journal:  Vaccine       Date:  2012-10-12       Impact factor: 3.641

6.  Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a.

Authors:  K R Turbyfill; S W Joseph; E V Oaks
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

7.  Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.

Authors:  D N Taylor; A C Trofa; J Sadoff; C Chu; D Bryla; J Shiloach; D Cohen; S Ashkenazi; Y Lerman; W Egan
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Evidence for long-term memory of the mucosal immune system: milk secretory immunoglobulin A against Shigella lipopolysaccharides.

Authors:  K C Hayani; M L Guerrero; G M Ruiz-Palacios; H F Gomez; T G Cleary
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

9.  Serum antibody to lipopolysaccharide antigens of Shigella species among U.S. military personnel deployed to Saudi Arabia and Kuwait during Operations Desert Shield and Desert Storm.

Authors:  K C Hyams; J D Malone; A L Bourgeois; R Hawkins; T L Hale; J R Murphy
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

10.  Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis.

Authors:  D Islam; B Wretlind; M Ryd; A A Lindberg; B Christensson
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.